NCT02597036 2025-10-23
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
Clinical Trials
25 trialsNCT05976334 2025-10-06
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
Takeda
Phase 1 Terminated
NCT05387265 2025-07-14
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
CytomX Therapeutics
Phase 1 Terminated
NCT04613492 2025-06-24
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
AstraZeneca
Phase 1 Terminated
NCT04405778 2025-05-29
A Study of TAK-102 in Adult With Previously-Treated Solid Tumors
Takeda
Phase 1 Terminated
NCT05164666 2025-05-29
A Study of TAK-103 in Adult With Solid Tumors
Takeda
Phase 1 Terminated
NCT04642365 2025-05-21
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
Hoffmann-La Roche
Phase 1 Terminated
NCT04237649 2025-05-18
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
Novartis
Phase EARLY_PHASE1 Terminated
NCT01127178 2024-10-10
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Terminated
NCT05996445 2024-08-23
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
Phase 1 Terminated
NCT03225105 2023-11-22
M3541 in Combination With Radiotherapy in Solid Tumors
EMD Serono
Phase 1 Terminated
NCT00819221 2022-08-30
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
AstraZeneca
Phase 1 Terminated
NCT00560716 2021-12-22
A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
Cyclacel Pharmaceuticals, Inc.
Phase 1 Terminated
NCT02587962 2021-01-14
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Medivir
Phase 1/2 Terminated
NCT03539484 2020-09-03
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT01369433 2020-09-01
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
AVEO Pharmaceuticals, Inc.
Phase NA Terminated
NCT02648711 2020-05-28
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Lumos Pharma
Phase 1 Terminated
NCT02678754 2020-01-23
CMIR
Caris Science, Inc.
Terminated
NCT02559492 2019-09-25
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT01431534 2019-03-01
MK-8669-056
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01463696 2018-08-27
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01930292 2016-03-24
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
Debiopharm International SA
Phase 1 Terminated
NCT01809912 2015-11-26
Safety Study of MG1102 in Patients With Solid Tumors
GC Biopharma Corp
Phase 1 Terminated
NCT01110083 2013-10-22
First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors
EMD Serono
Phase 1 Terminated
NCT00497731 2009-06-22
AZD1152 in Patients With Advanced Solid Malignancies-Study 1
AstraZeneca
Phase 1 Terminated